Global and United States Gynecological Progestin Drugs Market Report & Forecast 2022-2028

A progestogen, also referred to as a progestagen, gestagen, or gestogen, is a type of medication which produces effects similar to those of the natural female sex hormone progesterone in the body. A progestin is a synthetic progestogen. Progestogens are used most commonly in hormonal birth control and menopausal hormone therapy.
They can also be used in the treatment of gynecological conditions, to support fertility and pregnancy, to lower sex hormone levels for various purposes, and for other indications.

Market Analysis and Insights: Global and United States Gynecological Progestin Drugs Market

This report focuses on global and United States Gynecological Progestin Drugs market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Gynecological Progestin Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Progesterone accounting for % of the Gynecological Progestin Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospital Pharmacies was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

In United States the Gynecological Progestin Drugs market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Gynecological Progestin Drugs Scope and Market Size

Gynecological Progestin Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Gynecological Progestin Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Gynecological Progestin Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Gynecological Progestin Drugs market is segmented into

Progesterone

Dydrogesterone

Others

Segment by Application, the Gynecological Progestin Drugs market is segmented into

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Regional and Country-level Analysis

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Landscape and Gynecological Progestin Drugs Market Share Analysis

Gynecological Progestin Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Gynecological Progestin Drugs business, the date to enter into the Gynecological Progestin Drugs market, Gynecological Progestin Drugs product introduction, recent developments, etc.

The major vendors covered:

Merck

Teva Generics

Besins Healthcare

Virtus Pharmaceuticals, LLC

BionPharma

Aquatic Remedies

Zhejiang Xianju Pharmaceutical

Zhejiang Aisheng Pharmaceutical

Zhejiang Medicine

Hubei Dongxin Pharmaceutical

Tianjin Jinyao Pharmaceutical

Guangzhou Baiyunshan Mingxing Pharmaceutical